Scientific Reports,
Journal Year:
2024,
Volume and Issue:
14(1)
Published: May 10, 2024
COVID-19,
caused
by
SARS-CoV-2,
affects
neuronal
cells,
causing
several
symptoms
such
as
memory
loss,
anosmia
and
brain
inflammation.
Curcuminoids
(Me08
e
Me23)
curcumin
(CUR)
are
derived
from
Curcuma
Longa
extract
(EXT).
Many
therapeutic
actions
have
been
linked
to
these
compounds,
including
antiviral
action.
Given
the
severe
implications
of
especially
within
central
nervous
system,
our
study
aims
shed
light
on
potential
curcuminoids
against
SARS-CoV-2
infection,
particularly
in
cells.
Here,
we
investigated
effects
CUR,
EXT,
Me08
Me23
human
neuroblastoma
SH-SY5Y.
We
observed
that
significantly
decreased
expression
plasma
membrane-associated
transmembrane
protease
serine
2
(TMPRSS2)
TMPRSS11D,
consequently
mitigating
elevated
ROS
levels
induced
SARS-CoV-2.
Furthermore,
exhibited
antioxidative
properties
increasing
NRF2
gene
restoring
NQO1
activity
following
infection.
Both
effectively
reduced
replication
SH-SY5Y
cells
overexpressing
ACE2
(SH-ACE2).
Additionally,
all
compounds
demonstrated
ability
decrease
proinflammatory
cytokines
IL-6,
TNF-α,
IL-17,
while
specifically
INF-γ
levels.
Our
findings
suggest
curcuminoid
could
serve
a
agent
for
impact
context
system
involvement.
Journal of Medical Virology,
Journal Year:
2024,
Volume and Issue:
96(1)
Published: Jan. 1, 2024
Abstract
Although
the
COVID‐19
pandemic
has
officially
ended,
persistent
challenge
of
long‐COVID
or
post‐acute
COVID
sequelae
(PASC)
continues
to
impact
societies
globally,
highlighting
urgent
need
for
ongoing
research
into
its
mechanisms
and
therapeutic
approaches.
Our
team
recently
developed
a
novel
humanized
ACE2
mouse
model
(hACE2ki)
designed
explicitly
long‐COVID/PASC
research.
This
exhibits
human
expression
in
tissue
cell‐specific
patterns
akin
Ace2.
When
we
exposed
young
adult
hACE2ki
mice
(6
weeks
old)
various
SARS‐CoV‐2
lineages,
including
WA,
Delta,
Omicron,
at
dose
5
×
10
PFU/mouse
via
nasal
instillation,
demonstrated
distinctive
phenotypes
characterized
by
differences
viral
load
lung,
trachea,
turbinate,
weight
loss,
changes
pro‐inflammatory
cytokines
immune
cell
profiles
bronchoalveolar
lavage
fluid.
Notably,
no
mortality
was
observed
this
age
group.
Further,
assess
model's
relevance
studies,
investigated
tau
protein
pathologies,
which
are
linked
Alzheimer's
disease,
brains
these
post
infection.
findings
revealed
accumulation
longitudinal
propagation
tau,
confirming
potential
our
preclinical
studies
long‐COVID.
Neuropsychopharmacology Reports,
Journal Year:
2025,
Volume and Issue:
45(1)
Published: Jan. 4, 2025
ABSTRACT
COVID‐19
exhibits
not
only
respiratory
symptoms
but
also
neurological/psychiatric
rarely
including
delirium/psychosis.
Pathological
studies
on
provide
evidence
that
the
cytokine
storm,
in
particular
(epidermal
growth
factor)
EGF
receptor
(EGFR,
ErbB1,
Her1)
activation,
plays
a
central
role
progression
of
viral
replication
and
lung
fibrosis.
Of
note,
SARS‐CoV‐2
virus
(specifically,
S1
spike
domain)
mimics
directly
transactivates
EGFR,
preceding
inflammatory
process.
In
agreement,
anticancer
drugs
targeting
EGFR
such
as
Nimotuzumab
tyrosine
kinase
inhibitors
are
markedly
effective
COVID‐19.
However,
these
data
might
raise
provisional
caution
regarding
implication
psychiatric
disorder
schizophrenia.
The
author's
group
has
been
investigating
etiologic
neuropathologic
associations
signaling
with
There
significant
molecular
between
schizophrenia
ligand
levels
blood
well
brain.
addition,
perinatal
challenges
ligands
intraventricular
administration
to
rodents
monkeys
both
resulted
severe
behavioral
and/or
electroencephalographic
endophenotypes
relevant
this
disorder.
These
animal
models
display
postpubertal
abnormality
soliloquy‐like
self‐vocalization
intercortical
functional
connectivity.
Here,
we
discuss
neuropsychiatric
coronavirus
infection
its
interaction
system,
by
searching
related
literatures
PubMed
database
end
2023.
Medical Review,
Journal Year:
2024,
Volume and Issue:
5(1), P. 66 - 75
Published: July 1, 2024
Long
COVID,
as
currently
defined
by
the
World
Health
Organization
(WHO)
and
other
authorities,
is
a
symptomatic
condition
that
has
been
shown
to
affect
an
estimated
10
%-30
%
of
non-hospitalized
patients
after
one
infection.
However,
COVID-19
can
also
cause
organ
damage
in
individuals
without
symptoms,
who
would
not
fall
under
current
definition
COVID.
This
damage,
whether
or
not,
lead
various
health
impacts
such
heart
attacks
strokes.
Given
these
observations,
it
necessary
either
expand
COVID
include
recognize
COVID-19-induced
distinct
affecting
many
asymptomatic
infections.
It
important
consider
known
adverse
outcomes,
including
conditions
cancers,
be
until
harm
thresholds
are
reached.
Many
more
medical
identified
testing
than
those
recognized
through
reported
symptoms.
therefore
similarly
while
symptoms
associated
with
there
have
displaying
this
characterization
monitoring
Translational Pediatrics,
Journal Year:
2024,
Volume and Issue:
13(2), P. 318 - 328
Published: Feb. 1, 2024
In
the
context
of
global
pandemic
coronavirus
disease
2019
(COVID-19),
more
than
700
million
infections
and
millions
deaths
have
occurred
in
countries
around
world.
Currently,
two
main
sequelae
this
are
considered
to
occur
children,
namely,
multi-system
inflammatory
syndrome
children
long
COVID.
Among
these
two,
incidence
COVID
is
higher
its
impact
on
population
extensive,
which
focus
us.
However,
due
lack
relevant
studies
limitations
most
studies,
COVID-19
infection
lag
behind
those
adults,
but
they
begun
attract
attention
some
clinicians
researchers.
We
aim
summarize
current
knowledge
helping
pediatricians
researchers
better
understand
providing
guidance
research
clinical
treatment
it.
International Journal of Nanomedicine,
Journal Year:
2025,
Volume and Issue:
Volume 20, P. 669 - 684
Published: Jan. 1, 2025
Outer
membrane
vesicles
(OMVs)
derived
from
Gram-negative
bacteria
naturally
serve
as
a
heterologous
nano-engineering
platform,
functioning
effective
multi-use
nanovesicles
for
diagnostics,
vaccines,
and
treatments
against
pathogens.
To
apply
refined
OMVs
human
theranostic
applications,
we
developed
exposed
receptor-binding
domain
(RBD)
grafted
with
antigen
43
minimal
modular
system
targeting
angiotensin-converting
enzyme
2
(ACE2).
We
constructed
E.
coli-derived
using
the
autotransporter
to
display
RBD
referred
viral
mimetic
Ag43β700_RBD
OMVs.
Based
on
this,
protein
were
expressed
onto
Escherichia
coli
(E.
coli)
membrane.
Artificial
fabricated
by
self-assembly
through
disruption
of
chemical
detergent
mainly
containing
lysozyme.
Through
serial
centrifugation
purify
OMVs,
spherical
an
average
diameter
218
nm
obtained.
The
confirmation
was
performed
trypsin
treatment.
Our
had
impact
studies:
(i)
blockade
assay,
(ii)
enzyme-linked
immunosorbent
assay
(iii)
intracellular
uptake
neutralization
assay.
As
serodiagnostic
surrogates,
applied
ACE2
OMVs-ELISA
quantify
antibodies
(nAbs).
They
reduced
robust
immune
response
in
vitro,
especially
IL-6
IL-1β.
Experiments
mice,
successfully
proven
be
safe
effective;
they
produced
detectable
level
nAbs
39-58%
neutralisation
titres
lungs
brain
without
weight
loss.
may
therefore
nanovesicle-theranostic
platform
further
emerging
infectious
disease-related
diagnosis,
vaccination,
Medicine International,
Journal Year:
2025,
Volume and Issue:
5(2)
Published: Jan. 24, 2025
The
aim
of
the
present
study
was
to
clarify
current
status
persistent
symptoms
following
omicron
variants
COVID‑19
[long
COVID
(LC)]
and
risk
factors
associated
with
development
LC.
For
this
purpose,
a
cross‑sectional
survey
patients
treated
at
authors'
hospital
four
outpatient
clinics
conducted.
Questionnaires
about
post‑infection
condition
were
sent
by
post
3,399
patients.
A
comparison
made
infected
when
variant
prevalent
(omicron
group)
prior
that
(pre‑omicron
group).
Valid
responses
received
from
1,113
(32.7%)
percentages
in
whom
some
type
symptom
or
sequelae
continued
after
1,
3
6
months
44,
37
28%,
respectively,
pre‑omicron
group,
20,
12
9%,
group.
significantly
lower
In
multivariate
analysis
for
LC
months,
significant
hospitalization
[odds
ratio
(OR),
1.910;
P<0.01]
old
age
(OR,
1.120;
P<0.05).
Conversely,
incidence
vaccination
0.830;
P<0.01)
group
0.490;
P<0.01).
underlying
disease
(particularly
emphysema,
bronchial
asthma,
rheumatoid
collagen
hypertension)
(P<0.01).
On
whole,
demonstrates
>10%
even
Patients
who
required
conditions
require
careful
attention
